Oral Cavity Squamous Cell Carcinoma Clinical Trial
Official title:
Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
The purpose of this prospective, single-center, single-arm, open-label II phase observation clinical trial is to evaluate the efficacy and safety of Pembrolizumab immunoadjuvant therapy in patients with stage III-IVA oral squamous cell carcinoma. The primary end point is the pathological tumor remission rate of the primary tumor and regional lymph nodes after neoadjuvant immunotherapy (pTR-2: the proportion of necrotic tumor cells, keratin fragments and giant cells in tissue sections > 50%). The secondary endpoints are 1-year disease-free survival (DFS), 1-year overall survival (OS) and the incidence of adverse events, compared with historical data. In addition, we will check the relevant immune indicators, such as PD-L1 and CPS scores.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03650699 -
Biofeedback Rehabilitation to Improve Speaking and Eating in Public
|
N/A | |
| Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
| Terminated |
NCT03053960 -
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
|
||
| Recruiting |
NCT05876247 -
Articulatory Adaptation Following Oral Cancer Treatment
|
||
| Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
| Recruiting |
NCT05316688 -
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04858269 -
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03529604 -
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
|
||
| Completed |
NCT03028766 -
WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer
|
Phase 1 | |
| Recruiting |
NCT05681039 -
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
|
Phase 2 | |
| Completed |
NCT03510390 -
Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation
|
N/A | |
| Recruiting |
NCT05950737 -
Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience
|
N/A | |
| Recruiting |
NCT04333537 -
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03727594 -
Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
|
||
| Terminated |
NCT02582008 -
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
|
Early Phase 1 | |
| Recruiting |
NCT05749042 -
A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06097468 -
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04892875 -
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03784066 -
Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 |